Молекулярно-генетическое исследование наследственной предрасположенности к раку яичников
Диссертация
Впервые на российской выборке изучен вклад наследственной формы, связанной с мутациями в генах BRCA1 и BRCA2, в общую структуру заболеваемости РЯ. Выявленная частота мутаций в генах BRCA1 и BRCA2 относится к наиболее высоким среди изученных аналогичных выборок больныхв европейских странах. Основное число мутаций у российских больных РЯ наблюдается в гене ВЯСА1. Для выявления генетических факторов… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ ОБЗОР ЛИТЕРАТУРЫ Особенности канцерогенеза при наследственной форме рака яичников
- Ген ВЯСА1 и функции кодируемого им белка ВЯСА Ген ВЯСА2 и функции кодируемого им белка ВЯСА Клинические особенности наследственного рака яичников
- Исследование наследственной формы рака яичников
- Корреляция генотип-фенотип при мутациях в гене ВЯСА и ВКСА Однонуклеотидные полиморфизмы в генах В КС А1 и
- ВКСА МАТЕРИАЛЫ И МЕТОДЫ Пациенты
- Анализ первичной структуры генов ВКСА1 и ВЯСА Выделение геномной ДНК
- Полимеразная цепная реакция
- Конформационно — чувствительный гель электрофорез
- Автоматическое секвенирование
- Статистический анализ
- РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Частота мутаций в генах ВЯСА1 и ВЯСА2 при раке яичников
- Спектр мутаций в гене ВЯСА Анализ семейной истории больных раком яичников с мутациями в генах ВЯСА1 и ВЯСА Исследование однонуклеотидных полиморфизмов
- Изучение ОНП в выборке спорадического рака яичников
- Изучение ОНП в выборке ВЯСА-ассоциированного рака яичников
- Изучение ОНП в выборке ВЯСА-ассоциированного рака молочной железы
- Изучение ОНП в выборке спорадического рака молочной железы
- Исследование влияния на риск сочетаний генотипов по ОНП
- ВЫВОДЫ
Список литературы
- Давыдов, М.И. Статистика злокачественных новообразований в России и странах СНГ в 2005 г./ М. И. Давыдов, Е.М. Аксель// Вестник РОНЦ им. Н. Н. Блохина РАМН. 2007. — Т. 18. — № 2. — Прил. 1. С. 58.
- Животовский, JI.A. Популяционная биометрия / JI.A. Животовский. Москва. -Наука.- 1991.-271 с.
- Жорданиа, К.И. Злокачественные новообразования яичников / К.И. Жорданиа// Энциклопедия клинической онкологии. Москва. — 2004. — С. 427−442.
- Карпухин, A.B. Частоты однонуклеотидных полиморфизмов и мутаций в гене BRCA1 при наследственно обусловленном раке молочной железы и яичников/ A.B. Карпухин, Н. И. Поспехова, JI.H. Любченко, и др.// Докл. А.II. 2002. -Т.383. — № 5. — С. 706−709.
- Копнин, Б.П. Молекулярные механизмы канцерогенеза/ Б. П. Копнин // Энциклопедия клинической онкологии. / Под ред. М. И. Давыдова. Москва. -РЛС — Пресс. — 2004. — С.34−53.
- Копнин, Б.П. Нестабильность генома и онкогенез/ Б.П. Копнин// Молекулярная биология. 2007. — Т.41. — № 2. — С.369−3 80.
- Паниченко, И.В. Микроделеции в хромосомных локусах опухолей яичников: сопоставление с клинико-морфологическими факторами прогноза/ И. В. Паниченко, И. Б. Збровская, В. Н. Богатырев и др.// Российский онкологический журнал. 2006. — № 2. — С.26−31.
- Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA/ О. Ю. Реброва. Москва.-МедиаСфера. — 2002. — 312 с.
- Фогель Ф. Генетика человека. В трех томах. Перевод с англ./ Ф. Фогель, А. Мотульски.- Москва.- Мир.-1989.- 312 с.
- M.Antoniou, A.C. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes/ A.C. Antoniou, P.D.P. Pharoah, G. McMullan, et al. // British Journal of Cancer. 2002. — V.86. — P.76−83.
- Armstrong, K. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA½ mutations: a decision analysis/ K. Armstrong, J.S. Schwartz, T. Randall, et al. // J. Clin. Oncol.- 2004. V.22. -P.1045−1054.
- Auranen, A. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk/ A. Auranen, A.B. Spurdle, X. Chen et al. // Int. J. Cancer. 2003. — V.103. — № 3.-P.427−430.
- Baynes, C. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk/ C. Baynes, C.S. Healey, K.A. Pooley et al.// Breast Cancer Res. 2007. — V.9.- № 2.
- Baldeyron, C. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining/ C. Baldeyron, E. Jacquemin, J. Smith et al. // Oncogene. -2002.-№ 21.-P. 1401−1410.
- Bewtra, C. Hereditary ovarian cancer/ C. Bewtra, P. Watson, T. Conway et al. // Int. J. Gynecol. Pathol.-1992.-V.-ll, — P.180- 187.
- Boulton, S.J. Cellular functions of the BRCA tumour-suppressor proteins./ S.J. Boulton.- Biochem Soc Trans. 2006.- V.34.- P.633−645.
- Boyd, J. Specific keynote: hereditary ovarian cancer: what we know/ J. Boyd // Gynecol. Oncol.- 2003.-V.-88.-P.8−10.
- Boyd, J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer/ J. Boyd, Y. Sonoda, M.G. Federici et al. //JAMA.- 2001.-V.283.-P.2260 -2265.
- Breast Cancer Information Core (BIC). Режим доступа: http://www.nhgri.nih.gov/Intramuralresearch/Labtransfer/Bic/
- Cass, I. Improved survival in women with BRCA-associated ovarian carcinoma/ I. Cass, R.L. Baldwin, T. Varkey, R. Moslehi et al. // Cancer.- 2003.- V. 97.-P. 21 272 179.
- Chai, Y.L. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAFl/CIPl promoter/ Y.L. Chai, J. Cui, N. Shao et al. // Oncogene.- 1999.- V.18.- № 1, — P.263−268.
- Chen, P.L. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment./ P.L. Chen, C.F. Chen, Y. Chen// Proc. Natl. Acad. Sci. USA.- 1998, — V.95.-№ 9.- P.5287−5292.
- Dang, C.V. Function of the c-Myc oncogenic transcription factor/ C.V. Dang, L.M. Resar, E. Emison et al.// Exp. Cel. l Res. 1999.- V.253.- № 1.- P.63−77.
- David, B.Y. Effcct of BRCA mutations on the length of survival in epithelial ovarian tumors/ B.Y. David, A. Chetrit, G. Hirsh-Yechezkel et al. // J. Clin. Oncol.- 2002.-V.20.- P.463- 466.
- Davies, J.Y. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein/ A.A. Davies, J.Y. Masson, M.J. Mcllwraith ct al. // Mo. Cell. 2001 V.7.-№ 2. P.273−282.
- Deng, C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution/ C.X. Deng// Nucleic Acids Res.-2006.- V.34.-№ 5. -P.1416−1426.
- Dunning, A.M. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population/ A.M. Dunning, M. Chiano, N.R. Smith et al. // Hum. Mol. Genet. 1997, — V.6.- № 2.-P.285−289.
- Easton, D.F. Genome-wide association study identifies novel breast cancer susceptibility loci/ D.F. Easton, K.A. Poolcy, A.M. Dunning et al.// Nature.- 2007.-V.447.- № 7148.-P.1087−1093.
- Elledge, S.J. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients./ S.J. Elledge, A. Amon// Cancer Cell. 2002.-V.I.- № 2.- P.129−132.
- Esashi, F. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair/ F. Esashi, N. Christ, J. Gannon et al. // Nature.- 2005.-V.434.- № 7033.-P.598−604.
- Ford, D. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families/ D. Ford, D.F. Easton, M. Stratton et al. // Am. J. Hum. Genet. 1998. — V.62. — P.676−689.
- Foster, K. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer/ K. Foster, P. Harrington, J. Kerr et al. //Cancer. Res.- 1996.-V.56.-P.3622−3625.
- Friedman, L.S. The search for BRCA1/ L.S. Friedman, E.A. Ostermeyer, E. D Lynch et al.// Cancer Res.- 1994.- V.54.- № 24, — P.6374−6382.
- Fukasawa K. Centrosome amplification, chromosome instability and cancer development/ K. Fukasawa// Cancer Lett. 2005.- V.230.-№l.-P.6−19.
- Fuks, F. BRCA2 associates with acetyltransferase activity when bound to P/CAF / F. Fuks, J. Milner, T. Kouzarides// Oncogene. 1998.- V.17.- № 19, — P.2531−2534.
- Garci’a, A. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: association with carcinomas with serous differentiation/ A. Garci’a, E. Bussaglia, P. Machin et al. // Int. J. Gynecol. Pathol.- 2000.-V.19.- P. 152 -157.
- Gayther, S.A. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation/ S.A. Gayther, W. Warren, S. Mazoyer et al. // Nature Genet. 1995. — V. l 1. — P.428−433.
- Gayther, S.A. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes/ S.A. Gayther,-P. Russell, P. Harrington et al.// Am J Hum Genet. 1999.- V.65.-№ 4.- P.1021−1029.
- Gayther, S.A. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene/ S.A. Gayther, J. Mangion, P. Russell et al //Nat. Genet. -1997.-V. 15.- P.103−105.
- Ginolhac, S.M. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations/ S.M. Ginolhac, S. Gad, M. Corbex et al. // Cancer Epidemiol. Biomark. Prev. -2003.- V.12.- P.90−95.
- Godard, B. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study/ B. Godard, W.D. Foukes, D. Provencher et al.// Am. J. Obstet. Gynecol.- 1998.- V.179.- № 2.-P.403−410.
- Hanahan, D. The hallmarks of cancer/ D. Hanahan, RA. Weinberg // Cell.- 2000,-V.100.-№ 1P.57−70.
- Hankinson, S.E. A quantitative assessment of oral contraceptive use and risk of ovarian cancer/ S.E. Hankinson, G.A. Colditz, D.J. Hunter et al.// Obstet Gynecol.-1992, — V.80.-P.708—714.
- Healey, C.S. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability/ C.S. Healey, A.M. Dunning, M.D. Teare et al.// Nat. Genet.-2000.- V.26.-№ 3.-P.362−364.
- Heintz, A.P. Carcinoma of the ovary/ A.P. Heintz, F. Odicino, P. Maisonneuve et al. J. Epidemiol. Biostat.- 2001.-V.6.-№ 1.-P.107−138.
- Holt, J.T. Growth retardation and tumour inhibition by BRCA1/ J.T. Holt, M.E. Thompson, C. Szabo et al.//Nat. Genet.- 1996, — V.12.- P.298−302.
- Hughes, D.J. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation earners/ D.J. Hughes, S.M. Ginolhac, I. Coupie et al.// Cancer Epidemiol Biomarkers Prev.- 2005.- V.14.- №l.-P.265−267.
- Jacobs, I.J. Progress and challenges in screening for early detection of ovarian cancer/ I.J. Jacobs, U. Menon// Mol. Cell Proteomics.- 2004.- V.3.- № 4.-P.355−366.
- Janezic, S.A. Germline BRCA1 alterations in a population-based series of ovarian cancer cases/ S.A. Janezic, A. Ziogas, L.M. Krumroy et. al. // Hum. Mol. Genet. -1999. -V.8. № 5. -P.889−897.
- Jasin, M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection/ M. Jasin.// Oncogene.- 2002.-V.21 ,-№ 58.-P.8981−8993.
- Johannsson, O.T. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden./ O.T. Johannsson, J. Ranstam, A. Borg//H. J. Clin. Oncol. -1998.-V.16.-P. 397−404.
- Johnson, N. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility/ N. Johnson, O. Fletcher, C. Palles et al.// Hum. Mol. Genet.- 2007.-V.16.-№ 9.-P.1051−1057.
- Johnson, N.C. BRCA1 zinc RING finger domain disruption alters caspase response in ovarian surface epithelial cells/ N.C. Johnson, P.A. Kruk// Cancer Cell Int. -2002.-V.2.- № 1.- P.7.
- Kauff, N.D. Risk-reducing salpingo-oophorectomy in women with BRCA-1 or BRCA-2 mutation/ N.D. Kauff, J.M. Satagopan, M.E. Robson et al. // N. Engl. Med.-2002.-V.346.-P.1609−1615.
- Khoo, U.S. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations/ U.S. Khoo, H.Y. Ngan, A.N. Cheung, et al. //Hum. Mutat.-2000.-Vol.16.-P.88 89.
- Kim, Y.T. Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma/ Y.T. Kim, E.J. Nam, B.S. Yoon et al.// Gynecol. Oncol.- 2005. V.99, № 3. — P.585−590.
- Knudson, A.G. Mutation and cancer: neuroblastoma and pheochromocytoma/ A.G. Knudson, L.C. Strong // Am. J. Hum. Genet. 1972.-V.24.-№ 5.- P.514−532.
- Lakhani, S.R. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers/ S.R. Lakhani, S. Manek, F. Penault-Llorca et al. // Clin. Cancer Res.- 2004.- Vol.10.- P. 2473−2481.
- Lavin, M.F. The complexity of p53 stabilization and activation/ M.F. Lavin, N. Gueven// Cell Death Differ.- 2006.-V.13.-№ 6.-P.941−950.
- Levine, D.A. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series/D.A. Levine, J. Boyd//Cancer Res.-2001 .-V.61.-P.908−911.
- Lubinski, J. Cancer variation associated with the position of the mutation in the BRCA2 gene/ J. Lubinski, C.M. Phelan, P. Ghadirian et al.// Fam. Cancer.-2004,-V.3.-P.1−10.
- Majdak, E.J. Prognostic Impact of BRCA1 Pathogenic and BRCA1/BRCA2 Unclassified Variant Mutations in Patients with Ovarian Carcinoma/ E.J. Majdak, J. Debniak et al. // Cancer.- 2005, — Vol. 104.-P. 1004−1012.
- Malander, S. One in 10 ovarian cancer patients cany germ line BRCAI or BRCA2 mutations: results of a prospective study in Southern Sweden/ S. Malander, M. Ridderheim, A. Masback et. al. // Eur. J. Cancer.- 2004, — Vol.40.- № 3.-P.422−428.
- Miki, Y. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI/ Y. Miki, J. Swensen, D. Shattuck-Eidens et al.// Science. 1994.- V.266.-№ 5182.-P.66−71.
- Mizuta, R. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein/ R. Mizuta, J.M. LaSalle, H.L. Cheng et al. // Proc. Natl. Acad. Sci. U S A.- 1997, — V.94.-№ 13.-P.6927−6932.
- Monteiro, A.N. BRCAI: the enigma of tissue-specific tumor development/ A.N. Monteiro// Trends Genet.- 2003.- V.19.-№ 6.-P.312−315.
- Moslehi, R. BRCAI and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer/ R. Moslehi, W. Chu, B. Karlan et al. // Am. J. Hum. Genet.-2000.-Vol.66.-P. 1259- 1272.
- Narod, S.A. BRCAI and BRCA2: 1994 and beyond/ S. A .Narod, W.D. Foulkes// Nat. Rev. Cancer.- 2004.-V.4.-P.665−676.
- Narod, S.A. Genetics of breast and ovarian cancer/ S.A. Narod// Br. Med .Bull. -1994.- V.50.- № 3. P.656−676.
- Narod, S.A. Oral contraceptives and the risk of hereditary ovarian cancer/ S.A. Narod, H. Risch, R. Moslehi et al. //N. Engl. J. Med. 1998.- V.339.-P.424−428.
- Narod, S.A. Modifiers of risk of hereditary breast and ovarian cancer/ S.A. Narod// Nat. Rev. Cancer.- 2002.-V.2.- № 2.- P. l 13-.123.
- Narod, S.A. Ovarian cancer, oral contraceptives and BRCA mutations/ S.A. Narod, P. Sun, H.A. Risch // N. Engl. J. Med. 2001.-V.345.- P. 1706−1707.
- Pal, T. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases/ T. Pal, J. Permuth-Wey, J.A. Betts et al. // Cancer.- 2005,-Vol.104. P.2807−2816.
- Pejovic, T. Genetic changes in ovarian cancer/T. Pejovic // Ann. Med. 1995.-V.27. -№ 1.- P.73−78.
- Perkowska, M. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland/ M. Perkowska, I. BroZek, B. Wysocka et al. // Hum. Mutat. -2003. V.21.-№ 5. -P.553−554.
- Petalcorin, M.I. Stabilization of RAD-51-DNA filaments via an interaction domain in Caenorhabditis elegans BRCA2/ M.I. Petalcorin, V.E. Galkin, X. Yu, E.H. Egelman, S.J. Boulton // Proc. Natl. Acad. Sci. USA.- 2007.- V.104. № 20.-P.8299−8304
- Pharoah, P.D. The genetics of ovarian cancer/ P.D. Pharoah, B.A. Ponder // Best Pract. Res. Clin. Obstet. Gynaecol.- 2002.- Vol.16.-P.449- 468.
- Pharoah, P.D. Association between common variation in 120 candidate genes and breast cancer risk/ P.D. Pharoah, J. Tyrer, A.M. Dunning et al.// PLoS Genet. -2007.- V.3.- № 3.- P.42.
- Piver, M.S. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981−1991/ M.S. Piver, T.R. Baker, M.F. Jishi et al. //Cancer. 1993.- V.71.-P.582−588.
- Prat, J. Hereditary ovarian cancer/ J. Prat, A. Ribe, A. Gallardo //Human Pathology.2005.- Vol.36. P.861−870.
- Rebbeck T.R. Prophylactic oophorectomy in earners of BRCA1 mutations/ T.R. Rebbeck, H.T. Lynch, S.L. Neuhausen et al. // N. Engl. J. Med.- 2002, — Vol.346.-P.1616- 1622.
- Rebbeck, T.R. Modification of BRCA1-associated breast cancer risk by the polymorphic androgenreceptor CAG repeat/ T.R. Rebbeck, P.W. Kantoff, K. Krithivas et al.// Am. J. Hum. Genet. 1999.- V.64. — P. 1371−1377.
- Risch H.A. Parity, contraception, infertility and the risk of pithelial ovarian cancer/ H.A. Risch, L.D. Marrett, G.R. Howe// Am. J. Epidemiol.-1994.-V.140.-P.585−597.
- Risch, H.A. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer/ H.A. Risch, J. McLaughlin,
- D. Cole et al. //Am. J. Hum. Genet.- 2001.- Vol.68.-P.700- 710.
- Rosen, E.M. BRCA1 in hormonal carcinogenesis: basic and clinical research/ E.M. Rosen, S. Fan, C. Isaacs// Endocr. Relat. Cancer.- 2005, — V.12.- № 3.- P.533−548.
- Sambrook, J. Molecular cloning: a laboratory manual 2nd edn. / Sambrook J., Fritch
- E.F., Maniatis T. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 1989.
- San Filippo, J. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide/ J. San Filippo, P. Chi, M.G. Sehorn et al. // J Biol Chem.2006. V.281. -№ 17. — 1649−1657.
- Sankaran, S. Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function/ S. Sankaran, L.M. Starita, A.M. Simons et al. //Cancer Res. 2006.- V.66. — № 8. — P.4100−4107.
- Sharan, S.K. Identification and characterization of a microsatellite marker within murine BRCA2 gene/ S.K. Sharan, A. Bradley // Mamm. Genome. 1997. — V.8. -№ 1. -P.79.
- Shaw, P.A. Histopatologic feature of genetically determined ovarian canccr/ P.A. Shaw, J. McLaughlin, R.P. Zweemer et al. // Int. J Gynecol. Pathol.- 2002.- V.21.-P.407 411.
- Shin, S. BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription/ S. Shin, I.M. Verma// Proc. Natl. Acad. Sei. USA.- 2003. -V.100. -№ 12. P.7201−7206.
- Sowter, H.M. BRCA1 and BRCA2 as ovarian cancer susceptibility genes/ H.M. Sowter, A. Ashworth// Carcinogenesis. 2005.- V.26.- № 10. — P. 1651−1656.
- Spurdle, A.B. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years/ A.B. Spurdle, J.L. Hopper, X. Chen et al.// Cancer Epidemiol Biomarkers Prev. 2002.- V. 11. — № 4. — P.413−416.
- Stoppa-Lyonnet, D. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic/ D. Stoppa-Lyonnet, P. Laurent-Puig, E. Laurent et al. // Am. J. Hum. Genet. 1997. — V.60. — P.1021−1030.
- Tavtigian, S.V. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds/ S.V. Tavtigian, J. Simard, J. Rommens et al. // Nat Genet. 1996. -V.12. — № 3. —P.333−337.
- Thompson, D. Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position/ D. Thompson, D. Easton //Cancer Epidemiol. Biomarkers Prev. 2002. — V. l 1. — № 4. — P. 329−336.
- Turner, N. Targeting the DNA repair defect of BRCA tumours/ N. Turner, A. Tutt, A. Ashworth // Curr Opin Pharmacol.- 2005. V.5. — № 4. — P.388−393.
- Verhoog, L.C. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families/ L.C. Verhoog, A.M.W. Van den Ouweland, E. Berns et. al. // Eur. J. of Can. 2001. -V.37. — P.2082−2090.
- Vogelstein, B. Cancer genes and the pathways they control/ B. Vogelstein, K.W. Kinzler. Nat. Med. 2004. — V. 10. — № 8. — P.789−799.
- Wenham, R.M. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer/ R.M. Wenham, J.M. Schildkraut, K. McLean et al. // Clin Cancer Res. 2003. — V.9. -№ 12. — P.4396−4403.
- Werness, B.A. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer/ B.A. Werness, A.M. Afify, K.L. Bielat et al. // Hum. Pathol. 1999, — V.30.-P.151−157.
- Werness, B.A. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features/ Werness B.A., Eltabbakh G.H. // Int. J. Gynecol. Pathol.- 2001, — V.20.-P.48 63.
- Wilson, K. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas/ K. Wilson, L. Ramos, M.R. Villasenor et al. // Nat. Genet.-1999.- V.21.-P.236- 240.
- Wong, A.K. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. I A.K. Wong, R. Pero, P.A. Ormonde et al. J Biol Chem. 1997. — V.272. — № 51. — P.31 941 -31 944.
- Wooster, R. Identification of the breast cancer susceptibility gene BRCA2/ R. Wooster, G. Bignell, J. Lancaster et al.//Nature. -1995. -V.378.- № 6559.-P.789−792
- Wooster, R. Breast and ovarian cancer. Genomic medicine/ R. Wooster, B.L. Weber//N. Engl. J. Med.- 2003.- Vol.348.-P.2339 2347.
- Wu, L.C. Identification of a RING protein that can interact in vivo with the BRCA1 gene product/ L.C. Wu, Z.W. Wang, J.T. Tsan ct al. // Nat Genet.- 1996 V.14. -№ 4. -P.430−440.
- Yang, H. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction/ H. Yang, Q. Li, J. Fan et al. // Nature. 2005. — V.433. -№ 7026. — P.653−657.
- Yang, H. BRCA2 function in DNA binding and recombination from a BRCA2-DSSl-ssDNA structure / H. Yang, P.D. Jeffrey J. Miller et al. // Science. 2002. -13,-V.297. -№ 5588.-P. 1837−1848.
- Zikan, M. Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients/ M. Zikan, P. Pohlreich, J. Stribrna // J. Genet.-2005.-V.84. № 1.- P.63−67.
- Zweemer, R.P. Clinical and genetic evaluation of thirty ovarian cancer families/ R.P. Zweemer, R.H. Verheijen, J.J. Guille et al. // Am. J. Obstet. Gynecol.-1998.-V.178.-P.85−90.